Modulation of mAb quality attributes using microliter scale fed‐batch cultures

A high‐throughput DoE approach performed in a 96‐deepwell plate system was used to explore the impact of media and feed components on main quality attributes of a monoclonal antibody. Six CHO‐S derived clonal cell lines expressing the same monoclonal antibody were tested in two different cell culture media with six components added at three different levels. The resulting 384 culture conditions including controls were simultaneously tested in fed‐batch conditions, and process performance such as viable cell density, viability, and product titer were monitored. At the end of the culture, supernatants from each condition were purified and the product was analyzed for N‐glycan profiles, charge variant distribution, aggregates, and low molecular weight forms. The screening described here provided highly valuable insights into the factors and combination of factors that can be used to modulate the quality attributes of a molecule. The approach also revealed specific intrinsic differences of the selected clonal cell lines ‐ some cell lines were very responsive in terms of changes in performance or quality attributes, whereas others were less affected by the factors tested in this study. Moreover, it indicated to what extent the attributes can be impacted within the selected experimental design space. The outcome correlated well with confirmations performed in larger cell culture volumes such as small‐scale bioreactors. Being fast and resource effective, this integrated high‐throughput approach can provide information which is particularly useful during early stage cell culture development. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 30:571–583, 2014

[1]  N. Hooper,et al.  Families of zinc metalloproteases , 1994, FEBS letters.

[2]  M. Hentze,et al.  Balancing Acts Molecular Control of Mammalian Iron Metabolism , 2004, Cell.

[3]  Jean-Luc Teillaud,et al.  Impact of Glycosylation on Effector Functions of Therapeutic IgG † , 2010, Pharmaceuticals.

[4]  F. Gòdia,et al.  Considerations on the lactate consumption by CHO cells in the presence of galactose. , 2006, Journal of biotechnology.

[5]  S. Iida,et al.  Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. , 2007, Molecular immunology.

[6]  Hervé Broly,et al.  Cell culture medium improvement by rigorous shuffling of components using media blending , 2012, Cytotechnology.

[7]  M. Neville,et al.  Divalent cation activation of galactosyltransferase in native mammary Golgi vesicles. , 1990, The Journal of biological chemistry.

[8]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[9]  Martin Gawlitzek,et al.  Identification of cell culture conditions to control N‐glycosylation site‐occupancy of recombinant glycoproteins expressed in CHO cells , 2009, Biotechnology and bioengineering.

[10]  H. Ganther,et al.  Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. , 1999, Carcinogenesis.

[11]  Yoshiro Saito,et al.  Cell Death Caused by Selenium Deficiency and Protective Effect of Antioxidants* , 2003, Journal of Biological Chemistry.

[12]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[13]  Bo Zhang,et al.  Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody. , 2010, Journal of pharmaceutical sciences.

[14]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[15]  Scott Estes,et al.  Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function , 2008, Biotechnology and bioengineering.

[16]  Z. Li,et al.  Optimal and consistent protein glycosylation in mammalian cell culture. , 2009, Glycobiology.

[17]  Ashraf Amanullah,et al.  Novel micro‐bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed‐batch CHO cultures , 2010, Biotechnology and bioengineering.

[18]  W. Duetz,et al.  Microtiter plates as mini-bioreactors: miniaturization of fermentation methods. , 2007, Trends in microbiology.

[19]  G. N. Rogers,et al.  Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system , 2007, Biotechnology and bioengineering.

[20]  Jun Luo,et al.  Probing of C‐terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media , 2012, Biotechnology and bioengineering.

[21]  Yao-ming Huang,et al.  Discovery and Investigation of Misincorporation of Serine at Asparagine Positions in Recombinant Proteins Expressed in Chinese Hamster Ovary Cells , 2009, The Journal of Biological Chemistry.

[22]  Ashraf Amanullah,et al.  Comparative metabolite analysis to understand lactate metabolism shift in Chinese hamster ovary cell culture process , 2012, Biotechnology and bioengineering.

[23]  Wai Lam W Ling,et al.  Role of iron and sodium citrate in animal protein‐free CHO cell culture medium on cell growth and monoclonal antibody production , 2011, Biotechnology progress.

[24]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[25]  H. E. Johansson,et al.  Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells , 2013, Proceedings of the National Academy of Sciences.

[26]  B. Vallee,et al.  Zinc coordination, function, and structure of zinc enzymes and other proteins. , 1990, Biochemistry.

[27]  V. Quarmby,et al.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities , 2012, mAbs.

[28]  X. Zhong,et al.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications , 2013, International journal of cell biology.

[29]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[30]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[31]  C. Kahana,et al.  The Role of Polyamines in Supporting Growth of Mammalian Cells Is Mediated through Their Requirement for Translation Initiation and Elongation*♦ , 2010, The Journal of Biological Chemistry.

[32]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[33]  E. Stadtman,et al.  Nonenzymatic cleavage of proteins by reactive oxygen species generated by dithiothreitol and iron. , 1985, The Journal of biological chemistry.

[34]  H. Broly,et al.  A high-throughput media design approach for high performance mammalian fed-batch cultures , 2013, mAbs.

[35]  B. Scallon,et al.  Engineering host cell lines to reduce terminal sialylation of secreted antibodies , 2010, mAbs.

[36]  S. Gorfien,et al.  An HPLC-MALDI MS method for N-glycan analyses using smaller size samples: Application to monitor glycan modulation by medium conditions , 2009, Glycoconjugate Journal.

[37]  Gary J Lye,et al.  Microwell engineering characterization for mammalian cell culture process development , 2010, Biotechnology and bioengineering.

[38]  Marcella Yu,et al.  Effects of cell culture conditions on antibody N‐linked glycosylation—what affects high mannose 5 glycoform , 2011, Biotechnology and bioengineering.

[39]  A. Ambrogelly,et al.  Assessment of AMBRTM as a model for high-throughput cell culture process development strategy , 2012 .

[40]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[41]  Daniela Bumbaca,et al.  Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics , 2012, The AAPS Journal.

[42]  Nigel Jenkins,et al.  Post-translational Modifications of Recombinant Proteins: Significance for Biopharmaceuticals , 2008, Molecular biotechnology.

[43]  Marcella Yu,et al.  Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.

[44]  K. Kashiwagi,et al.  Modulation of cellular function by polyamines. , 2010, The international journal of biochemistry & cell biology.

[45]  Xiaoping Z He,et al.  Analysis of charge heterogeneities in mAbs using imaged CE , 2009, Electrophoresis.

[46]  D. Eccles,et al.  A Germ Line Mutation in the Death Domain of DAPK-1 Inactivates ERK-induced Apoptosis* , 2007, Journal of Biological Chemistry.

[47]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[48]  Michael C. Borys,et al.  Identification of cell culture conditions to control protein aggregation of IgG fusion proteins expressed in Chinese hamster ovary cells , 2012 .

[49]  R Thorpe,et al.  Fragmentation of Therapeutic Human Immunoglobulin Preparations , 1995, Vox sanguinis.

[50]  M B Sliwkowski,et al.  Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. , 2000, Biotechnology and bioengineering.

[51]  Kai Griebenow,et al.  Effects of glycosylation on the stability of protein pharmaceuticals. , 2009, Journal of pharmaceutical sciences.

[52]  K. Brew,et al.  Specificity and Mechanism of Metal Ion Activation in UDP-galactose:β-Galactoside-α-1,3-galactosyltransferase* , 2001, The Journal of Biological Chemistry.

[53]  S L Morrison,et al.  Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. , 1998, Journal of immunology.

[54]  Matthieu Stettler,et al.  Tools for high-throughput process and medium optimization. , 2014, Methods in molecular biology.

[55]  R. Ionescu,et al.  Fragmentation of monoclonal antibodies , 2011, mAbs.

[56]  M. Butler,et al.  Effects of Ammonia and Glucosamine on the Heterogeneity of Erythropoietin Glycoforms , 2002, Biotechnology progress.

[57]  Reed J. Harris,et al.  Effect of Copper Sulfate on Performance of a Serum‐Free CHO Cell Culture Process and the Level of Free Thiol in the Recombinant Antibody Expressed , 2008, Biotechnology progress.

[58]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[59]  David Pollard,et al.  A review of advanced small‐scale parallel bioreactor technology for accelerated process development: Current state and future need , 2011, Biotechnology progress.

[60]  M A Smith,et al.  Specific cleavage of immunoglobulin G by copper ions. , 2009, International journal of peptide and protein research.

[61]  R. Timpl,et al.  Two non‐contiguous regions contribute to nidogen binding to a single EGF‐like motif of the laminin gamma 1 chain. , 1994, The EMBO journal.

[62]  J. P. Pêgas Henriques,et al.  The Influence of Micronutrients in Cell Culture: A Reflection on Viability and Genomic Stability , 2013, BioMed research international.

[63]  Niki S. C. Wong,et al.  An investigation of intracellular glycosylation activities in CHO cells: Effects of nucleotide sugar precursor feeding , 2010, Biotechnology and bioengineering.

[64]  P. Salmon,et al.  A novel function for selenium in biological system: Selenite as a highly effective iron carrier for Chinese hamster ovary cell growth and monoclonal antibody production , 2006, Biotechnology and bioengineering.

[65]  R. Stevenson,et al.  β-Galactosidase Gene Mutations in Patients With Slowly Progressive GM1 Gangliosidosis , 1997, Journal of child neurology.

[66]  John A. Tainer,et al.  Structure and mechanism of copper, zinc superoxide dismutase , 1983, Nature.

[67]  Jongkyeong Chung,et al.  Selenite suppresses hydrogen peroxide‐induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3‐K/Akt pathways , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  J. T. Saari,et al.  Copper deficiency decreases complex IV but not complex I, II, III, or V in the mitochondrial respiratory chain in rat heart. , 2007, The Journal of nutrition.

[69]  W. Xu,et al.  Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies , 2012, mAbs.

[70]  Cleo Kontoravdi,et al.  Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns , 2010, Biotechnology progress.

[71]  D. Richardson,et al.  The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.

[72]  Alex Eon-Duval,et al.  Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach , 2012, Biotechnology progress.

[73]  Peifeng Chen,et al.  Effects of elevated ammonium on glycosylation gene expression in CHO cells. , 2006, Metabolic engineering.

[74]  Michael W. Laird,et al.  Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing , 2010, Biotechnology and bioengineering.

[75]  P. V. van Berkel,et al.  Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose , 2011, Biotechnology and bioengineering.

[76]  S. Elliott,et al.  Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. , 2005, Journal of pharmaceutical sciences.

[77]  Peiqing Zhang,et al.  The sweet tooth of biopharmaceuticals: Importance of recombinant protein glycosylation analysis , 2012, Biotechnology journal.

[78]  T. Michiels,et al.  Mutations That Affect the Tropism of DA and GDVII Strains of Theiler's Virus In Vitro Influence Sialic Acid Binding and Pathogenicity , 2002, Journal of Virology.

[79]  B. Imperiali,et al.  Metal ion dependence of oligosaccharyl transferase: implications for catalysis. , 1995, Biochemistry.

[80]  G. Marx,et al.  Site-specific modification of albumin by free radicals. Reaction with copper(II) and ascorbate. , 1986, The Biochemical journal.

[81]  S. Yoon,et al.  Substitution of glutamine by glutamate enhances production and galactosylation of recombinant IgG in Chinese hamster ovary cells , 2010, Applied Microbiology and Biotechnology.

[82]  Paul Chen,et al.  Control of misincorporation of serine for asparagine during antibody production using CHO cells , 2010, Biotechnology and bioengineering.

[83]  Shujun Bai,et al.  Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. , 2011, Biotechnology and bioengineering.

[84]  D. James,et al.  Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro , 2005, Biotechnology progress.

[85]  Mauricio Vergara,et al.  Advances in improving mammalian cells metabolism for recombinant protein production , 2013 .

[86]  K. Williams Interactions of polyamines with ion channels. , 1997, The Biochemical journal.

[87]  Nigel Jenkins,et al.  Getting the glycosylation right: Implications for the biotechnology industry , 1996, Nature Biotechnology.

[88]  D. James,et al.  CHO cell line specific prediction and control of recombinant monoclonal antibody N‐glycosylation , 2013, Biotechnology and bioengineering.

[89]  Tom Vink,et al.  N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG , 2009, Biotechnology progress.

[90]  Rachel Bareither,et al.  Automated disposable small scale reactor for high throughput bioprocess development: A proof of concept study , 2013, Biotechnology and bioengineering.

[91]  B. Scallon,et al.  Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. , 2007, Molecular immunology.

[92]  Kiran Mukhyala,et al.  Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.

[93]  Amber Haynes Fradkin,et al.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models. , 2009, Journal of pharmaceutical sciences.

[94]  F. Naider,et al.  Substrate recognition by oligosaccharyltransferase. Studies on glycosylation of modified Asn-X-Thr/Ser tripeptides. , 1983, The Journal of biological chemistry.

[95]  T. H. Nguyen,et al.  Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. , 1995, Biochemistry.

[96]  Martin Gawlitzek,et al.  Effect of cell culture medium components on color of formulated monoclonal antibody drug substance , 2013, Biotechnology progress.

[97]  N. Seiler,et al.  Polyamines and apoptosis , 2005, Journal of cellular and molecular medicine.